Tokenizing Data to Improve Individual Health with Datavant

We have now entered a universe of “determinants of health” ranging from medical debt to housing to medication access to transportation…literally all things impact health that happen outside a doctor’s office.

So is healthcare taking this into account? How are we helping those with substance abuse, rare cancers and unmanageable chronic conditions?

On today’s episode of Healthcare Rethink, host Brian Urban, sits down with Claire Manneh, Head of Provider Research at Datavant, to talk about how the intuitive approach of tokenizing data is transforming how the healthcare ecosystem is reaching patients and improving lives!

Tune in to learn more about Claire’s public health background and her path to Datavant on this energizing episode!

The two discuss:

  1. What tokenization means and what it can do in healthcare and beyond
  2. How Claire’s work impacts health equity, health improvement
  3. Claire’s hopes for enabling lasting positive impact across the eco-system relative to data tokenization

Claire Manneh is the Head of Provider Research at Datavant. She graduated from the University of California, Berkeley and obtained a Bachelor’s Degree in Political Science and Government; Public Health Degree, Political Science, and Government.

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…